Shopping Cart
Remove All
Your shopping cart is currently empty
SHR-1701 is a novel bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused with the extracellular domain of TGFβ receptor II. SHR-1701 has antitumour activity and can be used in solid tumour research.

| Description | SHR-1701 is a novel bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused with the extracellular domain of TGFβ receptor II. SHR-1701 has antitumour activity and can be used in solid tumour research. |
| Synonyms | Retlirafusp alfa |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | PD-L1/TGFβ |
| Cas No. | 2891860-17-4 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.